Cassandra Quave | |
---|---|
Born | Arcadia, Florida | June 2, 1978
Citizenship | United States of America |
Alma mater | Emory University (BS) Florida International University (PhD) |
Children | 4 |
Scientific career | |
Fields | Ethnobotany |
Institutions | Emory University School of Medicine Emory University |
Thesis | An ethnopharmacological approach to multidrug -resistant Staphylococcus aureus: Evaluation of Italian plants used in the traditional healing of skin disease (2008) |
Doctoral advisor | Dr. Bradley C. Bennett |
Website | www |
Cassandra Leah Quave (born June 2, 1978) is an American ethnobotanist, herbarium curator, and associate professor [1] at Emory University. Her research focuses on analyzing natural, plant-based medicine of indigenous cultures to help combat infectious disease and antibiotic resistance. [2] In particular, she studies bacterial biofilm inhibition and quorum-sensing inhibition of botanical extracts for inflammatory skin conditions. [3]
Born in Arcadia, Florida, Quave's interest in science and medicine began early, stemming from the extended time she spent in hospitals. [2] At age three, congenital birth defects prompted an amputation below the knee in her right leg. After surgery, she required follow-up treatment for complications from an MRSA (Methicillin-resistant Staphylococcus aureus) infection. [2] [4] This experience would provide the basis of her adolescent science fair project about drug resistance in Escherichia coli , as well as her later research projects. [4] [5]
In her undergraduate years at Emory University, she pursued a double bachelor's of science in Human Biology as well as Anthropology, which she earned in 2000. [2] [5] [6] A college course in tropical ecology coupled with trips to Peru shifted her interest from medical school to instead pursuing a PhD through researching ethnobotany. In Peru, she saw the work of a traditional medicine man on children with parasitic worm infections in villages without access to pharmaceutical drugs. To her, the encounter illustrated how modern Western medicine has undermined the usefulness of traditional medicine. [2]
After earning her bachelor's degrees, Quave started her ethnobotany fieldwork in southern Italy between 2001 and 2003, before pursuing a doctoral program in biology at Florida International University. Under Dr. Bradley C. Bennett's guidance, she completed her doctoral dissertation in 2008, titled "An ethnopharmacological approach to multidrug-resistant Staphylococcus aureas: Evaluation of Italian Plants used in the Traditional Healing of Skin Disease." [5] [6]
Quave completed her first post-doctoral fellowship in microbial pathogenesis at the University of Arkansas for Medical Sciences between 2009 and 2011. Specifically, she continued her study of medicinal plants in Italy, focusing on anti-biofilm properties in MRSA. [5] Additionally, Quave completed a second post-doctoral teaching fellowship between 2011 and 2012 with the Emory University Center for Human Health. [5] [7]
The defensive mechanism of bacterial biofilms in resisting antimicrobial drugs comes from the ability of microbes to develop and hide within a protective extracellular matrix. Quave's work during her first post-doctoral fellowship focused on the significant biofilm-inhibiting activity of 10 individual botanical extracts from unique species of plants, something she believes could be utilized in new drug therapies. [8] Since then, one of her current research projects focuses on finding the specific compounds in the elmleaf blackberry plant ( Rubus ulmifolius) that contribute to the property. [3] [5] In doing so, Quave hopes to translate the biofilm inhibiting extracts into a wound management device such as bandages. [3]
Another major project of Quave's has been studying quorum-sensing inhibiting (QSI) activity in medicinal plants that prevent bacterial cells from effectively communicating, colonizing, and releasing toxins. [9] [10] Her focus has been upon both the Brazilian pepper tree extracts ( Schinus terebinthifolia ) and the European chestnut ( Castanea sativa ). According to Quave, these QSI extracts could help in the treatment of atopic dermatitis. [3] However, she acknowledges a number of difficulties of the drug development process. Aside from receiving FDA approval, there are the added difficulties of isolating the active compound and understanding the complex pharmacology of multiple extracts, if pursuing a mixture for increased efficacy. [11]
In 2021, Quave published "The Plant Hunter", a memoir focused on searching for plants with medicinal potential. [12]
Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin. It is often positive for catalase and nitrate reduction and is a facultative anaerobe that can grow without the need for oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning. Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA). The bacterium is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved.
In biology, quorum sensing or quorum signaling (QS) is the process of cell-to-cell communication that allows bacteria to detect and respond to cell population density by gene regulation, typically as a means of acclimating to environmental disadvantages.
Methicillin-resistant Staphylococcus aureus (MRSA) is a group of gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. It caused more than 100,000 deaths worldwide attributable to antimicrobial resistance in 2019.
Methicillin (USAN), also known as meticillin (INN), is a narrow-spectrum β-lactam antibiotic of the penicillin class.
Psiloxylon mauritianum is a species of flowering plant, the sole species of the genus Psiloxylon. It is endemic to the Mascarene Islands in the Indian Ocean.
Vancomycin-resistant Staphylococcus aureus (VRSA) are strains of Staphylococcus aureus that have acquired resistance to the glycopeptide antibiotic vancomycin. Bacteria can acquire resistant genes either by random mutation or through the transfer of DNA from one bacterium to another. Resistance genes interfere with the normal antibiotic function and allow bacteria to grow in the presence of the antibiotic. Resistance in VRSA is conferred by the plasmid-mediated vanA gene and operon. Although VRSA infections are uncommon, VRSA is often resistant to other types of antibiotics and a potential threat to public health because treatment options are limited. VRSA is resistant to many of the standard drugs used to treat S. aureus infections. Furthermore, resistance can be transferred from one bacterium to another.
Staphylococcus epidermidis is a Gram-positive bacterium, and one of over 40 species belonging to the genus Staphylococcus. It is part of the normal human microbiota, typically the skin microbiota, and less commonly the mucosal microbiota and also found in marine sponges. It is a facultative anaerobic bacteria. Although S. epidermidis is not usually pathogenic, patients with compromised immune systems are at risk of developing infection. These infections are generally hospital-acquired. S. epidermidis is a particular concern for people with catheters or other surgical implants because it is known to form biofilms that grow on these devices. Being part of the normal skin microbiota, S. epidermidis is a frequent contaminant of specimens sent to the diagnostic laboratory.
Flucloxacillin, also known as floxacillin, is an antibiotic used to treat skin infections, external ear infections, infections of leg ulcers, diabetic foot infections, and infection of bone. It may be used together with other medications to treat pneumonia, and endocarditis. It may also be used prior to surgery to prevent Staphylococcus infections. It is not effective against methicillin-resistant Staphylococcus aureus (MRSA). It is taken by mouth or given by injection into a vein or muscle.
Dicloxacillin is a narrow-spectrum β-lactam antibiotic of the penicillin class. It is used to treat infections caused by susceptible (non-resistant) Gram-positive bacteria. It is active against beta-lactamase-producing organisms such as Staphylococcus aureus, which would otherwise be resistant to most penicillins. Dicloxacillin is available under a variety of trade names including Diclocil (BMS).
Lysostaphin is a Staphylococcus simulans metalloendopeptidase. It can function as a bacteriocin (antimicrobial) against Staphylococcus aureus.
Phenol-soluble modulins (PSMs) are a family of small proteins, that carry out a variety of functions, including acting as toxins, assisting in biofilm formation, and colony spreading. PSMs are produced by Staphylococcus bacteria including Methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus epidermidis. Many PSMs are encoded within the core genome and can play an important virulence factor. PSMs were first discovered in S. epidermidis by Seymour Klebanoff and via hot-phenol extraction and were described as a pro-inflammatory complex of three peptides. Since their initial discovery, numerous roles of PSMs have been identified. However, due in part to the small size of many PSMs, they have largely gone unnoticed until recent years.
mecA is a gene found in bacterial cells which allows them to be resistant to antibiotics such as methicillin, penicillin and other penicillin-like antibiotics.
Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.
Ceftaroline fosamil (INN), brand name Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. Ceftaroline fosamil is a prodrug of ceftaroline. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. It retains some activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria, but its effectiveness is relatively much weaker. It is currently being investigated for community-acquired pneumonia and complicated skin and skin structure infection.
Totarol is a naturally produced diterpene that is bioactive as totarol. It was first isolated by McDowell and Easterfield from the heartwood of Podocarpus totara, a conifer tree found in New Zealand. Podocarpus totara was investigated for unique molecules due to the tree's increased resistance to rotting. Recent studies have confirmed totarol's unique antimicrobial and therapeutic properties. Consequently, totarol is a candidate for a new source of drugs and has been the goal of numerous syntheses.
Biofilm formation occurs when free floating microorganisms attach themselves to a surface. Although there are some beneficial uses of biofilms, they are generally considered undesirable, and means of biofilm prevention have been developed. Biofilms secrete extracellular polymeric substance that provides a structural matrix and facilitates adhesion for the microorganisms; the means of prevention have thus concentrated largely on two areas: killing the microbes that form the film, or preventing the adhesion of the microbes to a surface. Because biofilms protect the bacteria, they are often more resistant to traditional antimicrobial treatments, making them a serious health risk. For example, there are more than one million cases of catheter-associated urinary tract infections (CAUTI) reported each year, many of which can be attributed to bacterial biofilms. There is much research into the prevention of biofilms.
Staphylococcus pseudintermedius is a gram positive coccus bacteria of the genus Staphylococcus found worldwide. It is primarily a pathogen for domestic animals, but has been known to affect humans as well. S. pseudintermedius is an opportunistic pathogen that secretes immune modulating virulence factors, has many adhesion factors, and the potential to create biofilms, all of which help to determine the pathogenicity of the bacterium. Diagnoses of Staphylococcus pseudintermedius have traditionally been made using cytology, plating, and biochemical tests. More recently, molecular technologies like MALDI-TOF, DNA hybridization and PCR have become preferred over biochemical tests for their more rapid and accurate identifications. This includes the identification and diagnosis of antibiotic resistant strains.
Accessory gene regulator (agr) is a complex 5 gene locus that is a global regulator of virulence in Staphylococcus aureus. It encodes a two-component transcriptional quorum-sensing (QS) system activated by an autoinducing, thiolactone-containing cyclic peptide (AIP).
Kerry L. LaPlante is an American pharmacist, academic and researcher. She is the Dean at the University of Rhode Island College of Pharmacy. She is a Professor of Pharmacy and former department Chair of the Department of Pharmacy Practice at the University of Rhode Island, an adjunct professor of medicine at Brown University, an Infectious Diseases Pharmacotherapy Specialist, and the Director of the Rhode Island Infectious Diseases Fellowship and Research Programs at the Veterans Affairs Medical Center in Providence, Rhode Island.
MRSA ST398 is a specific strain of Methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus is a gram-positive, spherical bacterium that can cause a range of infections in humans and animals. And Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that is resistant to many antibiotics. The abbreviation "ST" in MRSA ST398 refers to the sequence type of the bacterium. MRSA ST398 is a clonal complex 398 (CC398). This means that the strain had emerged in a human clinic, without any obvious or understandable causes. MRSA ST398, a specific strain of MRSA, is commonly found in livestock, and can cause infections in humans who come into contact with infected animals.